171 results
Page 3 of 9
8-K
EX-99.1
ekt kb4uv
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
7zldgi6u0n6u07xmobe
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
h7lykm xyznwszpe43
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
6nsdi
11 May 22
Regulation FD Disclosure
7:01am
8-K
7a0fcigiuip8e14m2
1 Apr 22
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:05am
8-K
EX-99.1
irqfgonmhw 8l
1 Apr 22
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:05am
8-K
EX-99.1
54dtf
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
8-K
EX-10.1
75e 3o9u3227stb
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
8-K
EX-99.1
axge7bdgnkq
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
8-K
EX-10.2
7mj85 p3z1she1epeq11
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
424B5
k6sbtkgmuppxe88rv
31 Mar 22
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
ulb6l6z
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
8-K
EX-99.1
1n1ab kze
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
ap3 9h3jo
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
vmmdc
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am
8-K
EX-99.1
6kokt
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am